Adare Pharmaceuticals: New possibilities in taste masking
A significant challenge facing the pharmaceutical industry is patient adherence. Several factors, such as bitter taste, administration difficulty, dosing frequency, and inconvenience, are attributed to the lack of patient acceptance and adherence to a prescribed regimen.
A significant challenge facing the pharmaceutical industry is patient adherence. Several factors, such as bitter taste, administration difficulty, dosing frequency, and inconvenience, are attributed to the lack of patient acceptance and adherence to a prescribed regimen.
By understanding patient needs, Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health. Our innovative Microcaps® Taste Masking Technology can help address the issue of taste acceptability.
Microcaps® Taste Masking Technology
Microcaps® Taste Masking Technology can be used to improve taste and provide alternative dosage forms.
This technology achieves a uniform and efficient drug particle (crystal, granulate, or liquid) coating and may enhance overall patient adherence by improving the product’s acceptability.
How Microcaps® Taste Masking Technology works
Microencapsulation technology employs versatile and precise coating techniques to encapsulate individual drug particles. This process uses coacervation (ie, phase separation) and can also incorporate a spray-coating process, creating polymeric membranes of varying degrees of porosity and thickness to completely encapsulate drug-containing particles. The membrane improves taste by forming a barrier between the drug and taste buds in the mouth.
To learn more about Microcaps® Taste Masking Technology, contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com
©2015 Adare Pharmaceuticals, Inc.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.
